Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report.
axitinib
metastasectomy
periodic drug withdrawal schedule
type 2 papillary renal cell carcinoma
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
22
05
2020
accepted:
29
01
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
19
3
2021
Statut:
ppublish
Résumé
A 46-year-old man underwent right partial nephrectomy for type 2 papillary renal cell carcinoma (PRCC) in 2011. Lung metastasis and lymph node (LN) metastases around the inferior vena cave appeared in 2012. A right radical nephrectomy and extensive LN dissection was performed and the resection of lung metastasis was performed one month after the nephrectomy. Mediastinal LN metastases occurred in 2013, and resection of the affected LNs was performed. Sunitinib and zoledronic acid was started in 2014 because mediastinal LN swelling and multiple bone metastases appeared. Sunitinib treatment was stopped soon after due to adverse events and axitinib treatment was started. Axitinib was effective and the patient had stable disease for 30 months. Adverse events were successfully controlled by dose reduction and periodic drug withdrawal schedules (for example, 5 days on, 2 days off). Axitinib was further continued for 19 months as the metastatic lesions had progressed slowly. Temsirolimus treatment was started in 2019, but it was stopped after three cycles due to interstitial pneumonia. The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC.
Identifiants
pubmed: 33732457
doi: 10.3892/mco.2021.2233
pii: MCO-0-0-02233
pmc: PMC7907800
doi:
Types de publication
Journal Article
Langues
eng
Pagination
71Informations de copyright
Copyright: © Arai et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Clin Genitourin Cancer. 2018 Oct;16(5):e997-e1002
pubmed: 29903415
Eur Urol. 2016 May;69(5):866-74
pubmed: 26626617
Cancer Res Treat. 2018 Apr;50(2):488-494
pubmed: 28546525
Clin Genitourin Cancer. 2018 Dec;16(6):e1201-e1214
pubmed: 30224330
Clin Genitourin Cancer. 2017 Apr;15(2):e205-e208
pubmed: 27568124
Cancer. 2008 Apr 1;112(7):1480-8
pubmed: 18240184
Ann Oncol. 2015 Jun;26(6):1123-1128
pubmed: 25802238
Cancer Sci. 2010 Apr;101(4):963-8
pubmed: 20180805
Eur Urol. 2012 Dec;62(6):1013-9
pubmed: 22771265
J Urol. 2003 Sep;170(3):764-7
pubmed: 12913693
Jpn J Clin Oncol. 2013 Jul;43(7):747-51
pubmed: 23667154
Nihon Hinyokika Gakkai Zasshi. 2014 Jul;105(3):129-33
pubmed: 25158555
Ann Oncol. 2012 Aug;23(8):2108-2114
pubmed: 22228449
Lancet Oncol. 2016 Mar;17(3):378-388
pubmed: 26794930
Hinyokika Kiyo. 2016 Sep;62(9):465-471
pubmed: 27760971
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Med Oncol. 2009;26(2):202-9
pubmed: 19229667
Hinyokika Kiyo. 2018 Feb;64(2):45-48
pubmed: 29684948
Br J Cancer. 2013 Apr 16;108(7):1541-9
pubmed: 23531701
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659